FDA Inspection 1166599 — Mazyar Shadman, MD. MPH
The FDA completed an inspection of Mazyar Shadman, MD. MPH on Apr 5, 2022 in Seattle, WA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 5, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Seattle, WA (United States)
Additional Details
Clinical Investigator (CI)